Takeda Chemical Industries, Inc.

Takeda Pharmaceutical Company Limited

Takeda Pharmaceuticals U.s.a., Inc.

Keisuke Hirai

Giichi Goto

Yuji Ishihara

Takashi Ishikawa

Masaomi Miyamoto

Yasushi Shintani

Osamu Uchikawa

David L Baron

David Baron

The present invention provides a prophylactic or therapeutic agent for an autism spectrum disorder containing compound (I) having melatonin receptor affinity. A compound represented by the formula: wherein each symbol is as described in the specification, or a salt thereof.

Prophylactic or therapeutic agent for autism spectrum disorder

Pharmaceutical compositions and methods for treating and/or preventing age-related macular degeneration with melatonin analogues are provided.

Pharmaceutical compositions and methods for treating age-related macular degeneration with melatonin analogues

Use of idebenone and analogues against &bgr; amyloid induced cytotoxicity

A novel compound of the formula: ##STR1## wherein Ar represents an optionally substituted tricyclic condensed benzene ring group which includes at least one heterocyclic ring as a component ring; n represents an integer from 2 to 10; R.sup.1 represents H or an optionally substituted hydrocarbon group, which may be different from one another in the repetition of n; and Y represents an optionally substituted 4-piperidinyl, 1-piperazinyl or 4-benzyl-1-piperidinyl group, or a salt thereof, inhibiting excellent cholinesterase inhibitory activity and monoamine reuptake inhibitory activity, thus being useful as therapeutic and/or prophylactic medicaments of senile dementia.

Tricyclic condensed heterocyclic compounds their production and use

Tricyclic condensed heterocyclic compounds, their production and use

Growing community of inventors

Osaka, Japan

Keisuke Hirai